In the latest session, Altamira Therapeutics Ltd (NASDAQ: CYTO) closed at $2.07 down -11.91% from its previous closing price of $2.35. In other words, the price has decreased by -$0.2800 from its previous closing price. On the day, 316707 shares were traded.
Ratios:
For a deeper understanding of Altamira Therapeutics Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.27 and its Current Ratio is at 0.32.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTO now has a Market Capitalization of 4.30M and an Enterprise Value of 8.08M. Its current Enterprise Value per Revenue stands at 67.19 whereas that against EBITDA is -0.36.
Stock Price History:
Over the past 52 weeks, CYTO has reached a high of $52.00, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 1.9449, while the 200-Day Moving Average is calculated to be 5.2746.
Shares Statistics:
For the past three months, CYTO has traded an average of 1.21M shares per day and 6.45M over the past ten days. A total of 1.58M shares are outstanding, with a floating share count of 1.58M. Insiders hold about 0.06% of the company’s shares, while institutions hold 0.49% stake in the company. Shares short for CYTO as of Mar 15, 2024 were 61.73k with a Short Ratio of 0.05, compared to 60.44k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.36% and a Short% of Float of 3.36%.
Earnings Estimates
There are 0 different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
